Yahoo Finance

Management to Host Conference Call Today at 4:30 p.m. ET

Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024.

“Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB. “At the same time, we deepened and broadened our relationships with our investor community by expanding our self-clearing brokerage offerings and securing new partnerships like we recently announced with one of the largest and most active angel investor networks in the nation, TCA Venture Group.”

Marlett concluded, “On the heels of a successful IPO for Invizyne Technologies, a ‘Big Idea’ company we spun out from the UCLA laboratory to the public market using our complete process, I am happy to report that we have a robust pipeline of new opportunities in the final stages of diligence. As we head into 2025, we are focusing on scaling the number of deep technology ideas we turn into valuable public companies and increasing operational efficiency.”

Third Quarter 2024 and Subsequent Operational Highlights

• Launched and completed an initial public offering for Invizyne Technologies: On November 13, the leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, began trading on NASDAQ under the ticker symbol “IZTC.” MDB co-founded the company and currently owns approximately 48% of outstanding shares.

• Announced a collaboration with Mayo Clinic to advance an anti-senescence platform: We launched a new “Big Idea” company through a patent and know-how license agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention and involved a $150,000 upfront license fee to Mayo. Initially, MDB owns a 67% founding ownership stake in a new company with the option to invest up to $5 million more for additional equity.

• Enhanced our curation and diligence capabilities: We increased the number of trained analysts to thirteen across our organization. Year-to-date, this enabled us to screen 8,751 private and public companies and further examined 217 with the highest probability of becoming market leaders, which has resulted in a robust pipeline of potential “Big Ideas” to bring to market.

• Increased PatentVest engagements: Our integrated IP intelligence, strategy consulting, and IP law firm, which enables visionary companies to develop into technology leaders, worked with eight clients, up from three at the end of 2023. While revenue generation is in its early stages, our initial clients have enabled us to understand how to best position the business for growth and we remain optimistic about the prospects for the company.

• Expanded and deepened relationships with our unique investor community: Since the end of 2023, we increased our shareholder base by 15%, onboarded over 450 new brokerage accounts, increased assets under management from roughly $2 million to $28 million before taking into account the Invizyne IPO, and announced a new partnership with TCA Venture group to continue to expand awareness and participation in the only clearing and trading platform built for public venture investing.

• Reported consolidated financial results: On November 12, we filed Form 10-Q with the SEC, which reports consolidated results from all operations, including Invizyne since the IPO did not occur before the quarter end. During today’s investor call, a financial breakout of operations will be discussed. In future quarters, illustrations of separate operating performance will be provided via an “Investor Toolkit” to be used in conjunction with regularly scheduled Form 10-Q filings.